Joseph M. Palumbo MD - 16 Feb 2023 Form 4 Insider Report for BIOVIE INC. (BIVI)

Role
Chief Medical Officer
Signature
/s/ Joseph M Palumbo, MD
Issuer symbol
BIVI
Transactions as of
16 Feb 2023
Net transactions value
-$30,310
Form type
4
Filing time
12 Jul 2024, 18:02:10 UTC
Previous filing
18 Jan 2023
Next filing
03 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIVI Common Stock Tax liability $13,643 -2,476 -6.7% $5.51 34,672 16 Feb 2023 Direct
transaction BIVI Common Stock Tax liability $2,922 -2,476 -7.1% $1.18 32,196 15 Feb 2024 Direct
transaction BIVI Common Stock Award $0 +116,000 +360% $0.000000 148,196 24 Jun 2024 Direct F1
transaction BIVI Common Stock Tax liability $13,746 -29,000 -20% $0.4740 119,196 24 Jun 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIVI Stock Option (right to buy) Award $0 +156,000 $0.000000 156,000 24 Jun 2024 Common Stock 156,000 $0.4740 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock unit ("RSU") grant was approved by the compensation committee of the issuer's board of directors on June 10, 2024, which grant became effective on June 24, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vested in full on June, 24, 2024.
F2 The options vest in three equal annual installments beginning on June 24, 2024.